Negative modulation of NMDA receptor channel function by DREAM/calsenilin/KChIP3 provides neuroprotection?

KeWei Wang1,2* and Yun Wang2*

1 Department of Molecular and Cellular Pharmacology, State Key Laboratory of Natural and Biomimetic Drugs, Peking University School of Pharmaceutical Sciences, Beijing, China
2 Department of Neurobiology, Neuroscience Research Institute, Key Laboratory for Neuroscience, Ministry of Education, Peking University School of Basic Medical Sciences, Beijing, China

Edited by:
Jose R. Naranjo, Centro Nacional de Biotecnologia/Consejo Superior de Investigaciones Científicas, Spain

Reviewed by:
Felix Hernandez, Universidad Autonoma de Madrid, Spain
Laura Mateos, Karolinska Institutet, Sweden

*Correspondence:
KeWei Wang, Department of Molecular and Cellular Pharmacology, State Key Laboratory of Natural and Biomimetic Drugs, Peking University School of Pharmaceutical Sciences, Beijing, China.
E-mail: wangkw@bjmu.edu.cn
Yun Wang, Department of Neurobiology, Neuroscience Research Institute, Key Laboratory for Neuroscience, Ministry of Education, Peking University School of Basic Medical Sciences, Beijing, China.
E-mail: wangy66@bjmu.edu.cn

INTRODUCTION
Glutamate functions as the major excitatory neurotransmitter by binding to N-methyl-D-aspartate receptors (NMDARs) that are widespread in the central nervous system. The NMDARs constitute a major class of ionotropic glutamate receptors and play an essential role in synaptic transmission, plasticity, and memory. Activation of NMDARs results in cell membrane depolarization with an equilibrium potential near 0 mV, producing the excitatory postsynaptic potential (EPSP) and leading to an increase of Ca$^{2+}$ influx into the cell. The intracellular Ca$^{2+}$ can in turn function as a second messenger, mediating a variety of signaling cascades. Excessive activation of NMDARs by glutamate mediates neuronal damage in many neurological disorders including ischemia and neurodegenerative diseases (Choi et al., 1988; Sattler and Tymianski, 2001).

The NMDARs have long been considered the major target for the treatment of excitotoxicity-related neuronal injury, and a variety of antagonists or blockers of NMDARs have been developed. Unfortunately, the results of clinical trials have been disappointing because of the obvious side effects associated with blocking the physiological roles of NMDARs (Chen and Lipton, 2006). Therefore, a better understanding of the mechanism of how NMDARs can be modulated by regulatory proteins should help in the development of new therapeutic agents to counteract overactive NMDA receptor function, and may represent an alternative to treating NMDAR-mediated excitotoxic injury. This short review focuses on the specific negative modulation of NMDARs by a neuronal calcium sensor (NCS) protein, DREAM/calsenilin/KChIP3.
acids, is involved in tetrameric assembly (Mayer, 2006; Paoletti and Neyton, 2007; Stroebel et al., 2011). The second domain of about 300 amino acids is known as the agonist-binding domain (ABD) that precedes the TM1 domain. The ABD binds glycine (or D-serine) in the NR1 and NR3 subunits, whereas the NR2 ABD binds glutamate (Furukawa et al., 2005; Yao and Mayer, 2006). The pore loop (P loop), or the M2 region, forms the narrowest constriction of the channel ion conductance pathway and determines the permeation properties of NMDARs. The NMDARs feature an intracellular C-terminal tail of about 400–600 residues that has a strong diversity in its amino acid sequence. The C-terminal tails of NMDAR subunits contain a series of short motifs that interact with intracellular factors or binding partners involved in receptor trafficking, anchoring and signaling (Skeberdis et al., 2006; Ryan et al., 2008; Lau et al., 2010).

Activation of NMDARs requires a simultaneous binding of two co-agonists, glutamate, and glycine with different biophysical properties of ion permeation. The typical NMDARs contain NR2 subunits with properties of high permeability to Ca\(^{2+}\) and extracellular Mg\(^{2+}\) block at hyperpolarized membrane potentials (Wrighton et al., 2008; Singh et al., 2012). Different from conventional NR1/NR2 heterotetramers, NR3-containing NMDARs have unique properties with a five to tenfold decrease of Ca\(^{2+}\) permeability, insensitivity to Mg\(^{2+}\) block, and reduced single-channel conductance and open probability, functioning as a negative modulator for NMDA receptor channel function (Das et al., 1998; Sasaki et al., 2002; Nakanishi et al., 2009; Cavara et al., 2010; Henson et al., 2010).

MODULATION OF NMDAR FUNCTION BY INTRACELLULAR BINDING PARTNERS

NMDA receptors are also regulated by other intracellular signals and proteins, including calcium, protein kinases, protein phosphatase calcineurin, and calcium-sensitive proteins such as calmodulin (Legendre et al., 1993; Vytklicky, 1993; Lieberman and Mody, 1994; Tong et al., 1995; Ehlers et al., 1996). Calcium-dependent NMDA receptor desensitization and inactivation provides a feedback mechanism capable of regulating subsequent Ca\(^{2+}\) entry into the postsynaptic cell through NMDA channels (Figure 1).

So far, a number of NR1 or NR2 subunit binding partners have been identified in the postsynaptic density. The NR1 binding proteins include calmodulin (CaM) (Ehlers et al., 1996; Akyol et al., 2004), Ca\(^{2+}\)/CaM-dependent protein kinase II (CaMKII) (Leonard et al., 2002), α-actinin (Wyszynski et al., 1997; Merrill et al., 2007), tubulin (van Rossum et al., 1999), spectrin (Wechsler and Teichberg, 1998), neurofilament (Ehlers et al., 1998), and Yotiao (Lin et al., 1998). Calmodulin binding to the NR1 subunit is Ca\(^{2+}\) dependent and occurs with homomeric NR1 complexes, heteromeric NR1/NR2 subunit complexes from expression systems, and NMDA receptors from the brain. Calmodulin binding to NR1 causes a fourfold reduction in NMDA channel open probability, mediating the negative modulation of NMDAR function (Ehlers et al., 1998).

DREAM/calsenilin/KChIP3, A NEURONAL CALCIUM SENSOR AND CALCIUM BINDING EF-HAND PROTEIN

DREAM/calsenilin/KChIP3 is encoded by the same gene locus. The downstream regulatory element antagonist modulator (DREAM) protein, first identified in the nucleus as a Ca\(^{2+}\)-regulated transcriptional repressor through its binding to DNA at specific regulatory elements, contains four Ca\(^{2+}\)-binding EF-hand domains and belongs to the NCS family (Carrion et al., 1999; Burgoyne, 2007). DREAM was named for its ability to block gene expression in its Ca\(^{2+}\)-free form via direct binding with the downstream regulatory element (DRE) sequence in target genes such as preprodynorphin (PPD), c-fos, Hrk, Na\(^{+}\), and Ca\(^{2+}\) exchanger NCX3 (Carrion et al., 1999; Sanz et al., 2001; Gomez-Villafuertes et al., 2005). DREAM was also named calsenilin or Kv channel interacting protein 3 (KChIP3) (Buxbaum et al., 1998; An et al., 2000), indicating that DREAM/calsenilin/KChIP3 has multifunctional properties. In the nucleus the DREAM protein functions as a dimer, whereas outside the nucleus KChIP3 is a monomer and regulates the surface expression and gating kinetics of Kv4 channels (An et al., 2000; Kim and Sheng, 2004;
Scannevin et al., 2004; Pioletti et al., 2006; Wang et al., 2007; Wang, 2008).

DREAM/calsenilin/KChIP3 is preferentially expressed in the central nervous system, as well as in non-neuronal tissues (Link et al., 2004; D’Andrea et al., 2005; Savignac et al., 2005). DREAM/calsenilin/KChIP3 knock-out mice display a hypoalgesic phenotype, suggesting a critical role of DREAM/calsenilin/KChIP3 in pain modulation (Cheng et al., 2002). In addition, emerging evidence reveals the role of DREAM/calsenilin/KChIP3 in long-term potentiation (LTP) (Lilliehook et al., 2003) and learning and memory (Alexander et al., 2009; Fontan-Lozano et al., 2009), suggesting a possible connection between DREAM and NMDA function.

KChIP1–3 were initially identified from a rat brain library in yeast two-hybrid (YTH) screens using the cytoplasmic N-terminal domain (amino acids 1–180) of rat Kv4.3 as a bait (An et al., 2000). Similarly, KChIP4 from mouse and human was accidentally cloned using the C-terminal 43 amino acid residues of presenilin 2 (PS2, amino acids 406–448) as a bait in the YTH system (Morohashi et al., 2002). KChIP4, also known as calsenilin-like protein (CALP), binds to PS2 which is known to facilitate intramembranous γ-cleavage of γ-amyloid protein precursor (βAPP) (Morohashi et al., 2002).

KChIP1–4 (216 ∼ 256 amino acids) can co-immunoprecipitate and co-localize with either Kv4 from co-transfected cells or Kv4 α-subunits from tissues, and thus constitute integral components of native Kv4 channel complexes (Wang, 2008). KChIP1–4 all share a conserved carboxy-terminal core region that contains four EF-hand-like calcium binding motifs, but have a variable amino-terminal region that causes diverse modulation of Kv4 trafficking and channel function (An et al., 2000; Holmqvist et al., 2002; Scannevin et al., 2004; Cui et al., 2008; Liang et al., 2009, 2010).

**FUNCTIONAL INTERACTIONS BETWEEN DREAM AND NMDA RECEPTORS**

We and others have investigated mechanisms underlying the functional interactions between DREAM and NMDARs. Findings from co-immunoprecipitation experiments show that DREAM antibody can immunoprecipitate endogenous NR1 subunit and DREAM protein from rat hippocampal tissue (Zhang et al., 2010). In the reciprocal co-IP studies in HEK 293 cells expressing DREAM and NR1-1a (NR1a) proteins, NR1 antibody can also immunoprecipitate DREAM along with the NR1 subunit. GST pull-down assays reveal that the N-terminus of DREAM directly interacts with the NR1a C-terminus, and that the DREAM-NR1 interaction is sensitive to Ca2+ and depends on the EF hand domains of DREAM (Zhang et al., 2010).

PSD-95 is a major scaffolding protein in the postsynaptic density, tethering NMDARs to signaling proteins, and is critical for NMDA receptor function (Kim and Sheng, 2004). Wu et al. generated a line of transgenic mice (TgDREAM) over-expressing a dominant active DREAM mutant, and compared NMDA receptor-mediated EPSCs in TgDREAM and wild-type mice under conditions of various stimulation intensities (Wu et al., 2010). They found that the amplitude of NMDA receptor-mediated EPSCs in TgDREAM mice is significantly reduced compared to that in wild-type mice (Wu et al., 2010). In addition, LTD is significantly reduced in TgDREAM mice whereas LTP is not affected by DREAM, demonstrating that DREAM interacts with PSD-95, and that the interaction is negatively regulated by calcium (Wu et al., 2010). In Xenopus oocytes expressing NR2B-containing NMDARs alone or together with DREAM, two-electrode voltage clamp recordings show that, in the absence of DREAM, the peak currents of NMDA channels activated by glutamate (plus glycine) are suppressed by DREAM, and the current decrease is caused by a reduction in the density of NMDARs at the cell surface (Figure 1; Zhang et al., 2010).

Fontan-Lozano et al. recently provided another piece of evidence that DREAM negatively regulates the function of NMDA receptors (Fontan-Lozano et al., 2011). By taking advantage of mice lacking the DREAM protein, they demonstrated that the facilitated learning induced by decreased expression of Kv4.2 in *dream^−/−* mice requires the activation of NMDA receptors containing the NR2B subunit (Fontan-Lozano et al., 2011). This study not only indicates the significance of the balance between Kv4 channel function and NMDAR activity, but also suggests the formation of a functional complex between DREAM/Kv4.2/NMDARs that regulates the synaptic efficacy mediating synaptic plasticity and learning.

**NEUROPROTECTIVE EFFECT OF DREAM/calsenilin/KChIP3 OVER-EXPRESSION ON NEURONAL EXCITOTOXIC INJURY**

Excitotoxicity is caused by overactivation of NMDA receptor function, and inhibition of NMDARs can reverse the neuronal toxicity. The data available so far support both the pro-apoptotic and anti-apoptotic roles of DREAM. In general, the pro-apoptotic role of DREAM closely correlates with its interaction with presenilins, the production of amyloid beta (Aβ) and the modulation in Ca2+ signaling, whereas the anti-apoptotic role of DREAM is conferred by its transcriptional repressor activity on the apoptotic protein Hrk. Jo et al. reported that HeLa cells transiently transfected with DREAM exhibit the morphological and biochemical features of apoptosis and that expression of presenilin potentiates DREAM-induced apoptosis (Jo et al., 2001). Jo et al. also reported that DREAM expression increases in either human neuroblastoma SK-N-BE(2)c cells or rat neuroblastoma B103 cells after exposure to Aβ, but no other apoptotic inducers such as staurosporine, thapsigargin, and calcium ionophore A23187. The pro-apoptotic role of DREAM is selectively induced during Aβ toxicity. Because of the involvement of presenilins/γ-secretase in Aβ formation and neuronal death, DREAM coordinates with presenilin activity to play a crucial role in these processes through binding with the C-terminus of presenilins (Jo et al., 2003, 2004). Lilliehook et al. stably expressed DREAM in H4 neuroglioma cells which showed no initiation of apoptosis in the absence of apoptosis triggers, and the apoptosis-associated caspase and calpain activities were not affected by DREAM (Lilliehook et al., 2002). On the other hand, binding of the transcriptional repressor DREAM to the hrk gene avoids inappropriate Hrk expression and apoptosis in hematopoietic progenitor cell lines (Sanz et al., 2001, 2002). Nevertheless, the precise function of DREAM in pro-apoptosis and anti-apoptosis remains to be explored.
From our previous observations, we noticed that cell viability is affected by the amount of exogenous DREAM gene and the method of transfection. However, we could not observe any obvious morphological changes associated with cell death after the transfection of DREAM. To prove the cytoprotective role of DREAM, we utilized cell lines and primary cultured hippocampal neurons with DREAM overexpression or siRNA-mediated knockdown, and evaluated lactate dehydrogenase (LDH) leakage and propidium iodide (PI) uptake both in NMDA and oxygen-glucose deprivation (OGD) -induced excitotoxic injury models (Zhang et al., 2010). Administration of NMDA markedly increases the number of PI-positive cells (dead cells) in NMDAR-transfected CHO cells, whereas co-expression of DREAM greatly reduces PI-positive cells (Zhang et al., 2010). LDH leakage measurement is a sensitive index reflecting the extent of cell damage. Over-expression of DREAM suppresses the NMDA-induced LDH release. OGD is commonly used in vitro to mimic ischemia-refperfusion insult to the brain, and OGD treatment induces a significant increase of LDH release (Dawson et al., 1994). With over-expression of DREAM, however, OGD treatment induces a smaller increase in LDH release. These results indicate that the over-expression of DREAM attenuates NMDAR-mediated excitotoxicity (Zhang et al., 2010).

We have previously tested the effect of DREAM siRNA on NMDA-induced current and excitotoxic injury in hippocampal neurons (Zhang et al., 2010). Knockdown of endogenous DREAM with siRNA results in an increased amplitude of NMDA current recorded by whole-cell patch-clamp assays. DREAM siRNA also significantly exacerbates NMDA-induced cell death in hippocampal neurons. After NMDA exposure, PI-positive cells in the DREAM siRNA group increase compared with control siRNA, indicating the inhibitory effect of DREAM on NMDAR-mediated current and excitotoxic injury (Zhang et al., 2010).

CONCLUSIONS

The NCS protein DREAM/calsenilin/KChIP3 acts as an auxiliary subunit and suppresses NMDA receptor channel function. This negative modulation of NMDA receptor function by DREAM likely provides a feedback mechanism by which overactive NMDA receptors are inhibited. Therefore, targeting regulatory proteins of NMDARs may represent an alternative approach to treating NMDAR-mediated excitotoxic damage and providing neuroprotection.

ACKNOWLEDGMENTS

We would like to thank the members of our laboratories for their comments and Greg Vatcher for his careful proof-reading of this manuscript. This work was supported by research grants from the National Science Foundation of China to KeWei Wang (30970919) and to Yun Wang (81161120497, 30830044, and 30925015).

REFERENCES

Akyol, Z., Bartos, J. A., Merrill, M. A., Faga, L. A., Jaren, O. R., Shea, M. A., and Hell, J. W. (2004). Apo-calmodulin binds with its C-terminal domain to the N-methyl-D-aspartate receptor NR1 C domain. J. Biol. Chem. 279, 2166–2175.

Alexander, J. C., McDermott, C. M., Timur, T., Rands, V., Stelly, C., Karshon, D., Bowlby, M. R., An, W. F., Sweatt, J. D., and Schrader, L. A. (2009). The role of calsernilin/DREAM/KChIP3 in contextual fear conditioning. Learn. Mem. 16, 167–177.

An, W. F., Bowlby, M. R., Betting, M., Cao, J., Ling, H. P., Mendoza, G., Hinson, J. W., Mattsson, K. I., Strassle, B. W., Trimmer, J. S., and Rhodes, K. J. (2000). Modulation of A-type potassium channels by a family of calcium sensors. Nature 403, 553–556.

Burgoyne, R. D. (2007). Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signalling. Nat. Rev. Neurosci. 8, 182–193.

Butzbaum, J. D., Choi, E. K., Luo, Y., Lillichook, C., Crowley, A. C., Merriam, D. E., and Wasco, W. (1998). Calsernilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat. Med. 4, 1177–1181.

Carrion, A. M., Link, W. A., Ledo, F., Mellstrom, B., and Naranjo, J. R. (1999). DREAM is a Ca2+-regulated transcriptional repressor. Nature 398, 80–84.

Cavara, N. A., Orth, A., Hicking, G., Seebohm, G., and Hollmann, M. (2010). Residues at the tip of the pore loop of NR3B-containing NMDA receptors determine Ca2+ permeability and Mg2+ block. BMC Neurosci. 11, 133.

Chazot, P. L., and Stephenson, F. A. (1997). Molecular dissection of native mammalian forebrain NMDA receptors containing the NR1 C2 exon: direct demonstration of NMDA receptors comprising NR1, NR2A, and NR2B subunits within the same complex. J. Neurochem. 69, 2138–2144.

Chen, H. S., and Lipton, S. A. (2006). The NCS protein DREAM/calsenilin/KChIP3 acts as an auxiliary subunit and suppresses NMDA receptor channel function. This negative modulation of NMDA receptor function by DREAM likely provides a feedback mechanism by which overactive NMDA receptors are inhibited. Therefore, targeting regulatory proteins of NMDARs may represent an alternative approach to treating NMDAR-mediated excitotoxic damage and providing neuroprotection.

Ehlers, M. D., Fung, E. T., O’Brien, R. J., and Huganir, R. L. (1998). Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J. Neurosci. 18, 720–730.

Ehlers, M. D., Zhang, S., Bernhardt, J. P., and Huganir, R. L. (1996). Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit. Cell 84, 745–755.

Fontan-Lozano, A., Romero-Granados, R., del-Pozo-Martin, Y., Suarez-Pereira, I., Delgado-Garcia, J. M., Penninger, J. M., and Carrion, A. M. (2009). Lack of DREAM protein enhances learning and memory and slows brain aging. Curr. Biol. 19, 54–60.

Fontan-Lozano, A., Suarez-Pereira, I., Gonzalez-Forero, D., and Carrion, A. M. (2011). The A-current modulates learning via NMDA receptors containing the NR2B subunit. PLoS One 6:24915. doi: 10.1371/journal.pone.0024915

Furukawa, H., Singh, S. K., Mancuso, R., and Gouaux, E. (2005). Subunit arrangement and function in NMDA receptors. Nature 438, 185–192.

Gomez-Villafuertes, R., Torres, B., Barrio, I., Savignac, M., Gabellini, N., Rizzato, F., Pintado, B.,
cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4. J. Biol. Chem. 277, 14965–14975.

Nakanishi, N., Tsu, Sh., Yin, C., Jukovska, T., Zhang, D., Chen, H. S., Tong, G., and Lipton, S. A. (2009). Neuroprotection by the NR3A subunit of the NMDA receptor. J. Neurosci. 29, 5260–5265.

Paolotti, P., and Neyton, J. (2007). NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 7, 39–47.

Pioletti, M., Findeisen, F., Hura, G. L., and Minor, D. L. Jr. (2006). Three-dimensional structure of the KChIP1-Kv4.3 T1 complex reveals a cross-shaped octamer. Nat. Struct. Mol. Biol. 13, 987–995.

Ryan, T. J., Edes, R. D., Grant, S. G., and Komiyama, N. H. (2008). Evolution of NMDA receptor cytoplasmic interaction domains: implications for organisation of synaptic signalling complexes. BMC Neurosci. 9, 6.

Sanz, C., Horita, M., and Fernandez-Luna, J. L. (2002). Fas signaling and blockade of Bcl-Ab1 kinase induces apoptotic Hrk protein via DREAM inhibition in human leukemia cells. Haematologica 87, 903–907.

Sanz, C., Mellstrom, B., Link, W. A., Naranjo, J. R., and Fernandez-Luna, J. L. (2001). Interleukin-3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic Hrk gene in hematopoietic progenitor cells. EMBO J. 20, 2286–2292.

Sakai, F., Fulde, T., Prenkumar, L. S., Das, S., Cai, J., Talatova, M. V., Wong, H. K., Gong, X., Chan, S. F., Zhang, D., Nakanishi, N., Sucher, N. J., and Lipton, S. A. (2002). Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons. J. Neurophysiol. 87, 2052–2063.

Sattler, R., and Tymianski, M. (2001). Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol. Neurobiol. 24, 107–129.

Taylor, M., Stahl, M., Malakin, K., Somers, W., Mosyak, L., Bowly, M. R., Chanda, P., and Rhodes, K. J. (2004). Two N-terminal domains of Kv4.3 channels regulate binding to and modulation by KChIP1. Neuron 41, 587–598.

Schorge, S., and Colquhoun, D. (2003). Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. J. Neurosci. 23, 1151–1158.

Singh, P., Doshi, S., Saethling, J. M., Hockenberry, A. J., Patel, T. P., Geddes-Klein, D. M., Lynch, D. R., and Meaney, D. F. (2012). N-methyl-D-aspartate receptor mecanosensitivity is governed by C terminus of NR2B subunit. J. Biol. Chem. 287, 4348–4359.

Skeberdis, V. A., Chevalleure, V., Lau, C. G., Goldberg, J. H., Pettit, D. L., Suadicani, S. O., Lin, Y., Bennett, M. V., Yuste, R., Castillo, P. E., and Zuki, R. S. (2006). Fyn molecule. A regulates calcium permeability of NMDA receptors. Nat. Neurosci. 9, 501–510.

Stroebel, D., Carvalho, S., and Paolotti, P. (2011). Functional evidence for a twisted conformation of the NMDA receptor GluN2B subunit in a terminal domain. Neurupharmacology 60, 151–158.

Tong, G., Shepherd, D., and Jahn, C. E. (1995). Synaptic desensitization of NMDA receptors by calcineurin. Science 267, 1510–1512.

van Rossum, D., Kuhse, J., and Betz, H. (1999). Dynamic interaction between soluble tubulin and C-terminal domains of N-methyl-D-aspartate receptor subunits. J. Neurosci. 19, 4833–4844.

Vyklicky, L. J. (1993). Calcium-mediated modulation of N-methyl-D-aspartate (NMDA) responses in cultured rat hippocampal neurons. J. Physiol. 470, 575–600.

Wang, H., Yan, Y., Liu, Q., Huang, Y., Shen, Y., Chen, L., Chen, Y., Yang, Q., Hao, Q., Wang, K., and Chai, J. (2007). Structural basis for modulation of Kv4 K+ channels by auxiliary KChIP subunits. Nat. Neurosci. 10, 32–39.

Wang, K. (2008). Modulation by clamp: Kv4 and KChIP interactions. Neurochem. Res. 33, 1964–1969.

Wechsler, A., and Teichberg, V. I. (1998). Brain spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin. EMBO J. 17, 3931–3939.

Wrighton, D. C., Baker, E. J., Chen, P. E., and Wyllie, D. J. (2008). Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D
subunits expressed in Xenopus laevis oocytes. J. Physiol. 586, 211–225.

Wu, L. J., Mellstrom, B., Wang, H., Ren, M., Domingo, S., Kim, S. S., Li, X. Y., Chen, T., Naranjo, J. R., and Zhuo, M. (2010). DREAM (downstream regulatory element antagonist modulator) contributes to synaptic depression and contextual fear memory. Mol. Brain 3, 3.

Wyszynski, M., Lin, J., Rao, A., Nigh, E., Beggs, A. H., Craig, A. M., and Sheng, M. (1997). Competitive binding of alpha-actinin and calmodulin to the NMDA receptor. Nature 385, 439–442.

Yao, Y., and Mayer, M. L. (2006). Characterization of a soluble ligand binding domain of the NMDA receptor regulatory subunit NR3A. J. Neurosci. 26, 4559–4566.

Zhang, Y., Su, P., Liang, P., Liu, T., Liu, X., Liu, X. Y., Zhang, B., Han, T., Zhu, Y. B., Yin, D. M., Li, J., Zhou, Z., Wang, K. W., and Wang, Y. (2010). The DREAM protein negatively regulates the NMDA receptor through interaction with the NR1 subunit. J. Neurosci. 30, 7575–7586.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 16 February 2012; paper pending published: 01 March 2012; accepted: 15 March 2012; published online: 13 April 2012.